Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 12/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7654550 | 0.98 | KMT2A (0.36) | ASH1LKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL8366761 | 0.89 | ASH1L (0.37) | ASH1LKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL7663691 | 0.89 | ASH1L (0.38) | ASH1LKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL7664149 | 0.87 | CAMK2D (0.41) | — | |
| SCHEMBL7665495 | 0.85 | CAMK2D (0.41) | — | |
| SCHEMBL7657124 | 0.84 | CAMK2D (0.39) | ALDH1A1 | |
| SCHEMBL8366774 | 0.84 | ASH1L (0.34) | ASH1LKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL8367882 | 0.84 | RAB9A (0.44) | ASH1LKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL7666393 | 0.84 | CAMK2D (0.36) | — | |
| SCHEMBL7662560 | 0.83 | PDE4B (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1071683-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999046264-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 1999-09-16 | — | — | WO | disclosed |